Next Article in Journal
Crystallization Behavior of Isotactic Polybutene Blended with Polyethylene
Next Article in Special Issue
Newly Designed Quinazolinone Derivatives as Novel Tyrosinase Inhibitor: Synthesis, Inhibitory Activity, and Mechanism
Previous Article in Journal
Advances in Research of Short Peptides
Previous Article in Special Issue
Phytochemical Composition, Antioxidant Activity, α-Glucosidase and Acetylcholinesterase Inhibitory Activity of Quinoa Extract and Its Fractions
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 27
Issue 8
10.3390/molecules27082447
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Discovery of a Novel Inhibitor Structure of Mycobacterium tuberculosis Isocitrate Lyase

by
Changyuan Duan
1,
Qihua Jiang
2,
Xue Jiang
1,
Hongwei Zeng
1,
Qiaomin Wu
1,
Yang Yu
1 and
Xiaolan Yang
1,*
1
Key Laboratory of Medical Laboratory Diagnostics of the Education Ministry, College of Laboratory Medicine, Chongqing Medical University, No. 1, Yixueyuan Road, Yuzhong Dist, Chongqing 400016, China
2
College of Pharmacy, Chongqing Medical University, Chongqing 400016, China
*
Author to whom correspondence should be addressed.
Molecules 2022, 27(8), 2447; https://doi.org/10.3390/molecules27082447
Submission received: 8 March 2022 / Revised: 30 March 2022 / Accepted: 31 March 2022 / Published: 11 April 2022
(This article belongs to the Special Issue Discovery of Enzyme Inhibitors from Natural Products)
Browse Figures
Versions Notes

Abstract

:
Tuberculosis remains a global threat to public health, and dormant Mycobacterium tuberculosis leads to long-term medication that is harmful to the human body. M. tuberculosis isocitrate lyase (MtICL), which is absent in host cells, is a key rate-limiting enzyme of the glyoxylic acid cycle and is essential for the survival of dormant M. tuberculosis. The aim of this study was to evaluate natural compounds as potential MtICL inhibitors through docking and experimental verification. Screening of the TCMSP database library was done using Discovery Studio 2019 for molecular docking and interaction analysis, with the putative inhibitors of MtICL, 3-BP, and IA as reference ligands. Daphnetin (MOL005118), with a docking score of 94.8 and -CDOCKER interaction energy of 56 kcal/mol, was selected and verified on MtICL in vitro and M. smegmatis; daphnetin gave an IC50 of 4.34 μg/mL for the MtICL enzyme and an MIC value of 128 μg/mL against M. smegmatis, showing enhanced potential in comparison with 3-BP and IA. The interactions and essential amino acid residues of the protein were analyzed. In summary, natural daphnetin may be a promising new skeleton for the design of inhibitors of MtICL to combat dormant M. tuberculosis.

1. Introduction

Tuberculosis (TB) is caused by the lethal pathogen Mycobacterium tuberculosis (Mtb) and remains one of the deadliest infectious diseases worldwide [1]. Although the incidence of TB has declined, the increasing number of drug-resistant strains, especially multidrug-resistant (MDR) and super-drug-resistant (XDR) strains, have posed great challenges to the treatment of tuberculosis [2]. According to the WHO, 8.9–11 million people were infected with TB globally, with 1.1–1.2 million deaths occurring in 2019 [3]. Worldwide, there are approximately 500,000 cases of rifampicin-resistant TB (RR-TB), of which ~78% are MDR-TB; MDR/RR-TB occurs in 3.3% of new TB cases and 17.7% of treated TB cases. However, Mtb can live in the host for years without clinical manifestations, which is known as latent TB. TB has a latency period that is longer than that of any other infectious disease [4]. It is estimated that at least a quarter of the world’s population is latently infected by bacteria [4], of which approximately 5–15% will develop active TB when they become immunocompromised. The latent infection comprises approximately 90% of TB cases [5]. Treatment of latent TB infection is essential for controlling and eliminating TB worldwide to achieve the goal of the End TB Strategy by 2035. To date, the standard first-line treatment for drug-sensitive TB lasts for 6 months, including 2 months of rifampicin, isoniazid, ethambutol, and pyrazinamide, followed by rifampicin and isoniazid for approximately 4 months, for a complete eradication of active Mtb and to prevent dormant bacilli from developing into active TB. However, no drugs in the clinic are effective against dormant Mtb, except pyrazinamide, which is not used because of its high hepatotoxicity [6]. However, the treatment of drug-resistant TB requires more than 20 months [7]. Therefore, more effective anti-tuberculosis drugs are needed to fight latent TB and MDR/MDR-TB.
There are various mechanisms underlying the dormancy and survival of Mtb. In the host, phagocytized Mtb and those maintained in granuloma suffer from hypoxia, nutrient deprivation, limited carbon sources, and high concentrations of nitric oxide. Dormant Mtb can reinforce anaerobic metabolic pathways to accommodate hypoxia [8,9,10]. The glycolate cycle is an alternative pathway to the tricarboxylic acid cycle under hypoxia, which allows bacteria to grow by using glyoxalates or fatty acids as carbon sources and plays an important role in the survival of Mtb [4]. Isocitrate lyase (ICL) is a key rate-limiting enzyme involved in the glyoxylate cycle, bypassing several β-oxidation steps in the Krebs cycle to reversibly decompose isocitrate into succinic acid and glyoxylate and producing energy [11,12]. Additionally, the upregulated alanine dehydrogenase (Ald) catalyzes the conversion of pyruvate to alanine, glycine dehydrogenase catalyzes the conversion of glyoxyate to glycine, and NADH is oxidized to NAD [13]. Glyoxylate and pyruvate are provided by the glyoxylate cycle and the methylcitrate cycle, respectively, and are catalyzed by two isomers of isocitrate lyase (ICL1 and ICL2), which are encoded by the genes icl and aceA, respectively [14]. Deletion of either or both the ICL and aceA genes impairs Mtb survival in activated macrophages and reduces their virulence [15,16,17]. In the absence of ICL, Mtb did not survive in the latent TB model. Moreover, these two pathways are absent in the host. Therefore, M. tuberculosis isocitrate lyase (MtICL) is a potential drug target for latent bacteria that has attracted increasing research interest [4,6,18,19].
Most of the classical inhibitors of ICL are structural analogs of the products of ICL-catalyzed reactions, such as 3-bromopyruvic acid (3-BP) [20], an analog of glyoxylate, and itaconic acid (IA) [21] and 3-nitropropanoic acid (3-NP) [22], analogs of succinic acid. However, these inhibitors have weak inhibition ability and strong biological toxicity [14] and have not been applied clinically. Several potential ICL inhibitors based on high-throughput screening (HTS) have been reported, such as XHD-1/XHD-2 [23] and IMbI-3 [24] from the Chinese medicine compound library, synthetic compounds of 3-nitropropionamides with inhibition at nanomolar levels [25], heptapeptide [26] from the chemical synthesis library, and a phage peptide library.
Virtual screening (VS) provides a new approach and alternative to high-throughput screening, which can significantly save experimental costs. By target-based VS of small molecules against characteristic binding sites, the molecules were selected as hits with high binding ability to target according to docking scores and interaction analysis [27], and further, according to the favorable binding modes after molecular dynamic simulation. Finally, hits were verified by subsequent bioactivity tests. Recently, there have been reports of VS based on the MtICL structure for inhibitors with no enzymatic assays [28,29].
In this study, to mine a new skeleton for MtICL inhibitors from Chinese medicines, the TCMSP database (https://old.tcmsp-e.com/tcmsp.php, accessed on 13 November 2020), with a total of 12,811 natural compounds, was used for VS. First, based on the natural crystal structure of ICL (PDB:1F8M), the active site was determined for VS. Candidate compounds with docking scores over 80 and -CDOCKER interaction energies >50 kcal/mol were selected; their IC50 for MtICL and MIC against M. smegmatis were evaluated. Finally, MOL005118 (named as daphnetin hereafter), with potent inhibition and favorable pharmacokinetics, was found to be a promising new skeleton for MtICL inhibitors.

2. Results

2.1. Virtual Screening

In this study, 12,811 compounds were screened. The workflow is shown in Figure S1. First, 8784 compounds were selected from the preliminary screening following the Lipinski and Veber rules. Subsequently, rigid docking and flexible docking were performed in sequence on the compound library using two functional modules of LibDock and CDOCKER. LibDock was first applied for the fast loading of these compounds in rigid conformations to the binding pocket of MtICL according to the hotspot principle of target-ligand interaction. LibDock is suitable for the fast and accurate virtual screening of large-scale databases. X, Y, and Z were set as 18.621885, 39.857179, and 52.768100, respectively. The known MtICL inhibitors 3-BP and IA were used as reference ligands, and their scores after LibDock were 55.7 and 72.9, respectively. Small molecules with LibDock scores ≥80 were selected for flexible docking on CDOCKER with a CHARMm-based molecular dynamics (MD) algorithm [30]. CHARMm is the most widely used molecular dynamics field in computer simulations. It can perform energy calculations for either small or large molecules (proteins, nucleic acids, and sugars) including interaction and conformational energies, minimization, and dynamic behavior [31,32,33,34].
After CDOCKER docking, 60 compounds with a -CDOCKER interaction energy >50 kcal/mol were selected for the next step of manual selection. The mode of interaction of isocitrate as the natural substrate for MtICL was compared with the binding modes of the candidate compounds for MtICL. As shown in Figure 1, the oxygen atoms of the carbonyl and hydroxyl groups of isocitrate are the main hydrogen bond receptors, forming conventional hydrogen bonds with amino acid residues in the active sites, such as TYR89, GLY192, SER315, SER317, and THR347. In addition, HIS180, LYS189, HIS193, and ARG228 form electrostatic interactions with isocitrate. To simplify the picture, some amino acid residues with weak interaction forces are hidden. This is consistent with the reported situation of essential amino acid residues in the MtICL active site [35]. Similarly, consistent results are observed for the interactions of 3-BP and IA. As shown in Figure 2, GLY192, SER315, THR347, ASN313, and HIS193 of MtICL interact with the oxygen atoms of 3-BP. GLY192, HIS198, ASN313, SER315, SER317, and THR347 are key residues involved in hydrogen bonding. IA forms hydrogen bonds with GLY192, HIS193, ASN313, SER315, THR317, and THR347 of MtICL and forms electrostatic interactions with LYS189, HIS180, and ARG228. Depending on the -CDOCKER interaction energy >50 kcal/mol and the binding models consistent with those of the reference compounds to the essential amino acid residues of MtICL, as shown in the 2D diagrams (Table S1), 11 compounds with structures different from those natural substrate analogs were selected for further experimental verification (Table 1).
Daphnetin forms multiple interactions with MtICL residues, including π-alkyl interactions between the lactone ring and CYS191 and ASP108, and those between the phenol ring and CYS191, ASP108, and LEU348, in addition to the electrostatic attraction of HIS193 to the two oxygen atoms on the phenol moiety. In addition, a total of six amino acid residues (LYS189, GLY192, ARG228, GLU285, SER315, and SER317) form hydrogen bonds with carbonyl and hydroxide groups (Figure 3A). Other compounds also form hydrogen bonds with GLY192, ASN313, SER315, and other additional key residues (Table S1). The overlapping diagram shows a good structural similarity among the reference ligand, isocitrate, and daphnetin (Figure 4). Based on their interaction with MtICL, a certain number of hydrogen bond receptors, such as hydroxyl groups, are necessary for high inhibition potency against MtICL. These results can direct subsequent inhibitor development from daphnetin or others.

2.2. Enzyme Inhibitory Activity Assay

The inhibitory potency against MtICL of the 11 hits and reference ligands was determined using UV spectrophotometry. In preliminary assays of 11 compounds at 333 μM or 500 μg/mL, 2 (Table 1) exhibited over 50% inhibition against MtICL, while the others had no significant inhibitory effect. The most potent daphnetin was further subjected to the dose-dependent inhibition assay, which gave an IC50 = 4.34 μg/mL (Figure 3B), while 3-BP and IA showed an IC50 of 63.6 ± 2.8 μM and 38.6 ± 0.8 μM, respectively. Daphnetin is a potent inhibitor of MtICL and a promising lead compound that is worth subsequent structural optimization.

2.3. Antibacterial Activity Assay

Streptomycin and levofloxacin as the positive controls showed MICs of 0.5 μg/mL and <0.125 μg/mL, respectively. The MICs of 3-BP and IA were higher than those of positive controls. The MIC of daphnetin was smaller than those of 3-BP and IA but still inferior to those of the positive controls (Table 2), which may be due to the limited permeability across the cell wall of Mtb. The other compounds showed no obvious antibacterial activity at 256 μg/mL.

2.4. Pharmacokinetics of Daphnetin

ADMET calculations and toxicity predictions were performed for daphnetin and the two reference ligands, and the results are shown in Table 3 and Table 4. Daphnetin has good intestinal absorption and water solubility but low blood–brain barrier permeability. It has no inhibitory effect on CYP2D6, low non-binding with plasma proteins, and some hepatotoxic effects. In addition, rat oral LD50 and developmental toxicity potential (DTP) of daphnetin show low toxicity. The results of Ames show that none of the three compounds exhibit mutagenicity. As a result, daphnetin, with potent inhibition of MtICL but moderate antibacterial activity and hepatotoxicity, needs subsequent optimization or preparation as a prodrug to modify permeability and lessen potential toxicity.

2.5. Molecular Dynamics Simulation

MD simulations were performed to determine the optimal binding conformation of daphnetin against MtICL. The NPT ensemble was set at 200 ps. After the equilibrium stage was achieved, the average temperature reached 300 K. A total of 200 conformations were generated, and the average RMSD value was 2.1375 (Figure 5A), supporting that the simulated system of the receptor complex was well balanced and had no obvious deviation from the initial structure. The RMSF values fluctuate significantly in the region comprising residues 310–398 (Figure 5B), suggesting that these regions play an important role in protein function.

3. Discussion

An efficient MtICL inhibitor, daphnetin was discovered from the small molecule database of Traditional Chinese Medicine (TCMSP) by virtual screening with the known receptor-binding site. Daphnetin is a coumarin derivative, 7,8-dithydroxycoumarin. Comparing with the reference ligands, daphnetin had a higher inhibitory capacity against MtICL (IC50 = 4.34 μg/mL) but a moderate antibacterial effect. This undesirable antibacterial effect might be caused by limited permeability across the cell wall of Mtb.
Daphnetin was the first new drug in China and is mainly derived from Daphne Korean Nakai. It has a variety of pharmacological effects, including cardiotonic, anti-inflammatory, antithrombotic, and antitumor effects [44,45,46,47]. Clinically, it is used to treat cardiovascular diseases such as coronary heart disease [48] and thromboangiitis obliterans [49]. It was mechanically reported that daphnetin has inhibitory activity on a variety of protein kinases, such as EGFR, PKA, and PKC, with IC50 values of 7.67 μM, 9.33 μM, and 25.01 μM, respectively [43], and also inhibition of the survival of hepatocellular carcinoma cells through regulating the Wnt/β-catenin signaling pathway [47]. Extensive researches related a lot of coumarin derivatives to a wide range of biological activities [50,51,52,53], suggesting that the specificity of coumarin derivatives is still an open question. However, no association of Daphne Korean Nakai or daphnetin with anti-TB activity has been reported. What is more, 4-methylumbelliferone and daphnetin are both coumarin derivatives, with the difference of a 4-methyl group on 4-methylumbelliferone and an 8-hydroxyl on daphnetin. However, in this study, as shown in Table 1, there was a large difference in the affinity against MtICL of daphnetin and 4-methylumbelliferone, suggesting that the 8-hydroxyl group of daphnetin may play a key role in the specific inhibition against MtICL. As a result, daphnetin, rather than 4-methylumbelliferone, is the potent inhibitor of MtICL.
MtICL is the key rate-limiting enzyme in the glyoxylate cycle, which is essential for the survival of dormant Mtb but is absent in the host; potent inhibitors of MtICL are still rare [25]. In this study, through the high-throughput virtual screening of a natural medicine library, daphnetin was found to have a strong inhibitory effect on MtICL and moderate anti-TB activity. According to pharmacokinetics results, daphnetin has good solubility in water, good intestinal absorption, no mutagenicity, and low toxicity. Moreover, the favorable interactions with MtICL, and thus high affinity against MtICL, support daphnetin as a promising lead compound worthy of structural modification to improve membrane permeability. The simple structure and low molecular weight of daphnetin facilitate the structural modification to improve membrane permeability and pharmacological activity. The insertion of a long alkyl moiety at the C3 position generally improved the lipophilicity beneficial for cell penetration [44], and also the substitution with triazole [54] and theophylline moieties [55] may improve its anti-TB activity.
In conclusion, this study proposed daphnetin as a new lead skeleton targeting MtICL, which has the potential to be developed as an anti-tuberculosis drug targeting MtICL and effective against dormant Mtb. Further structural modifications are in progress.

4. Materials and Methods

4.1. Reagents

MtICL was expressed and purified as described previously [56]. The 3-BP was purchased from MCE (MedChemExpress, Shanghai, China). IA was purchased from Adamas (Adamas-beta, Shanghai, China). Daphnetin was purchased from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, USA). Streptomycin was purchased from TCI (TCI Shangha Chemical industry development Co., Ltd., Shanghai, China). Levofloxacin came from Solarbio (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China). Mycobacterium smegmatis mc2155 came from Guangdong Microbial Species Preservation Center.

4.2. Methods

4.2.1. Protein Preparation

The three-dimension crystal structure of MtICL bound with the inhibitor 3-BP (PDB:1F8M) was download from RCSB Protein Data Bank (http://www.rcsb.org, accessed on 5 January 2021). Protein structure was prepared by assigning partial charges, removing all the water molecules, and adding polar hydrogen atoms using Discovery Studio 2019 (DS) (BIOVIA Corp, San Diego, CA, USA). Considering the optimal pH of MtICL, the pH was set to 7.0. The sphere cavity accommodating 3-BP was defined as the active site for VS.

4.2.2. Ligand Preparation

A dataset of the Chinese medicine small molecules (12,811 compounds) was derived from TCMSP (https://old.tcmsp-e.com/tcmsp.php, accessed on 13 November 2020) in mol2 format and imported into DS. The library was screened by the Lipinski and Veber rules firstly. After that, the library was optimized by removing duplicates and enumerating isomers and tautomers, and their 3D conformations were generated. The pH values ranged from 6.5 to 8.5. Other parameters were set to default values.

4.2.3. Virtual Screening

From primary screening with LibDock module, small molecules with scores greater than or equal to 80 were selected. Then CDOCKER was used for precise docking. According to the resultant -CDOCKER interaction energy between each protein and compound conformation, compounds were selected with interaction energies >50 kcal/mol and structures other than those resembling the natural substrate citrate. Pymol 3.7 was used to visualize protein–ligand complexes. The same procedure was performed for the reference ligands.

4.2.4. Enzyme Inhibitory Activity Assay

Enzyme inhibitory activity was evaluated by monitoring the decreasing rate of absorbance (V = ∆A/min) of enzyme reaction coupled with NADH at 340 nm [57]. MtICL at 0.5 μg and compounds at different final concentrations were added to a 300 μL enzymatic reaction system (5 mM MgCl2, 5 mM L-cysteine, 1 mM EDTA, pH 6.8). The mixture was incubated at 37 °C for 10 min, then 2 mM isocitrate was added and incubated for 20 min. Finally, 2U LDH and 0.2 mM NADH were added, and then the absorbance reduction at 340 nm in 3 min after 3 s mixing was monitored at intervals of 10 s (∆A) under room temperature. The enzyme activity was calculated according to the extinction coefficient of NADH (ε = 6.22 × 103 mol−1·cm−1) [11]. A unit of the enzyme activity is defined as the amount of enzyme converting 1 μmol of substrate within 1 min. The percentage of inhibition of enzyme activity was calculated according to the following Equation (1):
Inhibition   rate % = | V − V 0 | V 0 × 100
V indicates the reaction rate with the inhibitor, V0 indicates the reaction rate without the inhibitor. Graphpad prism 9.0 was used for non-linear fitting of “dose–response curves” for inhibitors to obtain an IC50 value of the compound against MtICL.

4.2.5. Antibacterial Activity Assay

M. smegmatis Mc2155 is highly homologous to Mtb, but it grows rapidly and is noninfectious. Therefore, the compounds obtained by virtual screening were tested against M. smegmatis C2155 by mini-broth dilution test. M. smegmatis was cultured in Middlebrook 7H9 with OADC (10% Tween-80, 20% glycerol) and grew at 37 °C to a McTurbidities of about 0.5. M. smegmatis in culture was diluted at 1:1000 (about 1 × 105 CFU/mL). The initial solution of each compound in dimethyl sulfoxide (DMSO) or sterile deionized water was in a 2-fold continuous dilution in a 96-well microplate containing 0.1 mL 7H9 medium. After that, 0.1 mL diluted bacterial solution was added and cultured at 37 °C for at least 48 h, and then the colony growth was observed. Positive control without drugs and negative control without bacteria were set up. Visual minimum inhibitory concentration (Visual MIC) was defined as the minimum concentration of drug without bacterial growth on the microplate.

4.2.6. Pharmacokinetic Prediction and Dynamics Simulation of Hits

To evaluate the druggability properties of candidate hits, ADMET calculations and toxicity predictions were performed using the Calculate Molecular Properties module in DS. ADMET can contribute to the early elimination of compounds with poor performance in ADMET and avoid the later waste of the huge financial resources and manpower required for structural modification. The ADMET can be calculated as follows: aqueous solubility, blood–brain barrier penetration, CYP2D6 binding, hepatotoxicity, intestinal absorption, and plasma protein binding. Toxicity prediction aspects included Ames, Rat oral LD50 and others. Additionally, 3-BP and IA were set as controls.
Molecular dynamics (MD) simulation in NPT thermodynamic ensemble was performed based on the CHARMm36 force field. The solvent environment was added as normal saline; minimization of 1000 steps was performed using the steepest descent method, and the thermal equilibrium temperature was set at 300 K.

4.3. Statistical Analysis

All experiments were repeated three times. The results were expressed as mean ± standard deviation ( x ¯ ± s ).

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules27082447/s1, Figure S1: Schematic diagram of virtual screening procedure; Table S1: 2D diagram of compounds.

Author Contributions

Conceptualization, methodology, software, validation, formal analysis, investigation, data curation, writing—original draft, visualization, C.D.; software, investigation, Q.J.; investigation, resources, X.J., H.Z., Q.W. and Y.Y.; resources, methodology, supervision, formal analysis, writing—review & editing, project administration, funding acquisition, X.Y. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Natural Science Foundation of China (Grant No. 31570862), the Natural Science Foundation Project of Chongqing (CSTC2019jcyj-msxmX0166), and the Natural Science Foundation Project of Yuzhong District, Chongqing (20210132).

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds are available from the authors.

References

  1. Dheda, K.; Gumbo, T.; Maartens, G.; Dooley, K.E.; McNerney, R.; Murray, M.; Furin, J.; Nardell, E.A.; London, L.; Lessem, E.; et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir. Med. 2017, 5, 291–360. [Google Scholar] [CrossRef]
  2. Faridgohar, F. Finding new ways to combat multidrug-resistant Tuberculosis. Microb. Drug Resist. 2020, 26, 71–80. [Google Scholar] [CrossRef] [PubMed]
  3. World Health Organization. Global Tuberculosis Report 2020. Available online: https://apps.who.int/iris/handle/10665/336069 (accessed on 7 April 2021).
  4. Bhusal, R.P.; Bashiri, G.; Kwai, B.X.C.; Sperry, J.; Leung, I.K.H. Targeting isocitrate lyase for the treatment of latent tuberculosis. Drug Discov. Today 2017, 22, 1008–1016. [Google Scholar] [CrossRef] [PubMed]
  5. Gideon, H.P.; Flynn, J.L. Latent tuberculosis: What the host “sees”? Immunol. Res. 2011, 50, 202–212. [Google Scholar] [CrossRef] [Green Version]
  6. Campanico, A.; Harjivan, S.G.; Warner, D.F.; Moreira, R.; Lopes, F. Addressing Latent Tuberculosis: New Advances in Mimicking the Disease, Discovering Key Targets, and Designing Hit Compounds. Int. J. Mol. Sci. 2020, 21, 8854. [Google Scholar] [CrossRef]
  7. Grace, A.G.; Mittal, A.; Jain, S.; Tripathy, J.P.; Satyanarayana, S.; Tharyan, P.; Kirubakaran, R. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis. Cochrane Database Syst. Rev. 2019, 12, CD012918. [Google Scholar] [CrossRef]
  8. Shi, L.; Sohaskey, C.D.; Kana, B.D.; Dawes, S.; North, R.J.; Mizrahi, V.; Gennaro, M.L. Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration. Proc. Natl. Acad. Sci. USA 2005, 102, 15629–15634. [Google Scholar] [CrossRef] [Green Version]
  9. Sohaskey, C.D. Nitrate enhances the survival of Mycobacterium tuberculosis during inhibition of respiration. J. Bacteriol. 2008, 190, 2981–2986. [Google Scholar] [CrossRef] [Green Version]
  10. Sohaskey, C.D.; Wayne, L.G. Role of narK2X and narGHJI in hypoxic upregulation of nitrate reduction by Mycobacterium tuberculosis. J. Bacteriol. 2003, 185, 7247–7256. [Google Scholar] [CrossRef] [Green Version]
  11. Ibeji, C.U.; Salleh, N.A.M.; Sum, J.S.; Ch’ng, A.C.W.; Lim, T.S.; Choong, Y.S. Demystifying the catalytic pathway of Mycobacterium tuberculosis isocitrate lyase. Sci. Rep. 2020, 10, 18925. [Google Scholar] [CrossRef]
  12. Vanni, P.; Giachetti, E.; Pinzauti, G.; McFadden, B.A. Comparative structure, function and regulation of isocitrate lyase, an important assimilatory enzyme. Comp. Biochem. Physiol. B 1990, 95, 431–458. [Google Scholar] [CrossRef]
  13. Giffin, M.M.; Modesti, L.; Raab, R.W.; Wayne, L.G.; Sohaskey, C.D. Ald of Mycobacterium tuberculosis encodes both the alanine dehydrogenase and the putative glycine dehydrogenase. J. Bacteriol. 2012, 194, 1045–1054. [Google Scholar] [CrossRef] [PubMed]
  14. Honer Zu Bentrup, K.; Miczak, A.; Swenson, D.L.; Russell, D.G. Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis. J. Bacteriol. 1999, 181, 7161–7167. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Betts, J.C.; Lukey, P.T.; Robb, L.C.; McAdam, R.A.; Duncan, K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 2002, 43, 717–731. [Google Scholar] [CrossRef] [PubMed]
  16. Gould, T.A.; van de Langemheen, H.; Munoz-Elias, E.J.; McKinney, J.D.; Sacchettini, J.C. Dual role of isocitrate lyase 1 in the glyoxylate and methylcitrate cycles in Mycobacterium tuberculosis. Mol. Microbiol. 2006, 61, 940–947. [Google Scholar] [CrossRef] [PubMed]
  17. Munoz-Elias, E.J.; McKinney, J.D. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat. Med. 2005, 11, 638–644. [Google Scholar] [CrossRef] [Green Version]
  18. Nandakumar, M.; Nathan, C.; Rhee, K.Y. Isocitrate lyase mediates broad antibiotic tolerance in Mycobacterium tuberculosis. Nat. Commun. 2014, 5, 4306. [Google Scholar] [CrossRef]
  19. Sharma, R.; Das, O.; Damle, S.G.; Sharma, A.K. Isocitrate lyase: A potential target for anti-tubercular drugs. Recent Pat. Inflamm. Allergy Drug Discov. 2013, 7, 114–123. [Google Scholar] [CrossRef]
  20. Ko, Y.H.; McFadden, B.A. Alkylation of isocitrate lyase from Escherichia coli by 3-bromopyruvate. Arch. Biochem. Biophys. 1990, 278, 373–380. [Google Scholar] [CrossRef]
  21. McFadden, B.A.; Purohit, S. Itaconate, an isocitrate lyase-directed inhibitor in Pseudomonas indigofera. J. Bacteriol. 1977, 131, 136–144. [Google Scholar] [CrossRef] [Green Version]
  22. Schloss, J.V.; Cleland, W.W. Inhibition of isocitrate lyase by 3-nitropropionate, a reaction-intermediate analogue. Biochemistry 1982, 21, 4420–4427. [Google Scholar] [CrossRef] [PubMed]
  23. Bai, B.; Xie, J.P.; Yan, J.F.; Wang, H.H.; Hu, C.H. A high throughput screening approach to identify isocitrate lyase inhibitors from traditional Chinese medicine sources. Drug Dev. Res. 2006, 67, 818–823. [Google Scholar] [CrossRef]
  24. Liu, Y.; Zhou, S.; Deng, Q.; Li, X.; Meng, J.; Guan, Y.; Li, C.; Xiao, C. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis. Tuberculosis 2016, 97, 38–46. [Google Scholar] [CrossRef] [PubMed]
  25. Sriram, D.; Yogeeswari, P.; Methuku, S.; Vyas, D.R.; Senthilkumar, P.; Alvala, M.; Jeankumar, V.U. Synthesis of various 3-nitropropionamides as Mycobacterium tuberculosis isocitrate lyase inhibitor. Bioorgan. Med. Chem. Lett. 2011, 21, 5149–5154. [Google Scholar] [CrossRef]
  26. Liu, X.; Zang, Y.; Sun, B.; Yin, Y. Optimization of phage heptapeptide library-screening process for developing inhibitors of the isocitrate lyase homologue from Mycobacterium tuberculosis. Med. Chem. Res. 2013, 23, 2543–2553. [Google Scholar] [CrossRef]
  27. Wu, G.; Robertson, D.H.; Brooks, C.L.; Vieth, M. Detailed analysis of grid-based molecular docking: A case study of CDOCKER-A CHARMm-based MD docking algorithm. J. Comput. Chem. 2003, 24, 1549–1562. [Google Scholar] [CrossRef]
  28. Lee, Y.V.; Choi, S.; Wahab, H.; Lim, T.S.; Choong, Y.S. Applications of Ensemble Docking in Potential Inhibitor Screening for Mycobacterium tuberculosis Isocitrate Lyase Using a Local Plant Database. J. Chem. Inf. Modeling 2019, 59, 2487–2495. [Google Scholar] [CrossRef]
  29. Tiwari, A.; Kumar, A.; Srivastava, G.; Sharma, A. Screening of Anti-mycobacterial Phytochemical Compounds for Potential Inhibitors against Mycobacterium Tuberculosis Isocitrate Lyase. Curr. Top. Med. Chem. 2019, 19, 600–608. [Google Scholar] [CrossRef]
  30. Lee, H.J.; Jeong, P.; Moon, Y.; Choi, J.; Heo, J.D.; Kim, Y.C.; Han, S.Y. Characterization of LDD-2633 as a Novel RET Kinase Inhibitor with Anti-Tumor Effects in Thyroid Cancer. Pharmaceuticals 2021, 14, 38. [Google Scholar] [CrossRef]
  31. Liu, H.; Song, D.; Zhang, Y.; Yang, S.; Luo, R.; Chen, H.F. Extensive tests and evaluation of the CHARMM36IDPSFF force field for intrinsically disordered proteins and folded proteins. Phys. Chem. Chem. Phys. 2019, 21, 21918–21931. [Google Scholar] [CrossRef]
  32. Mu, J.; Liu, H.; Zhang, J.; Luo, R.; Chen, H.F. Recent Force Field Strategies for Intrinsically Disordered Proteins. J. Chem. Inf. Modeling 2021, 61, 1037–1047. [Google Scholar] [CrossRef] [PubMed]
  33. Rahman, M.U.; Rehman, A.U.; Liu, H.; Chen, H.F. Comparison and Evaluation of Force Fields for Intrinsically Disordered Proteins. J. Chem. Inf. Modeling 2020, 60, 4912–4923. [Google Scholar] [CrossRef] [PubMed]
  34. Bernard, R.B.; Robert, E.B.; Barry, D.O.; David, J.S. CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations. J. Comput. Chem. 1983, 4, 187–217. [Google Scholar] [CrossRef]
  35. Sharma, V.; Sharma, S.; Hoener zu Bentrup, K.; McKinney, J.D.; Russell, D.G.; Jacobs, W.R., Jr.; Sacchettini, J.C. Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nat. Struct. Mol. Biol. 2000, 7, 663–668. [Google Scholar] [CrossRef] [PubMed]
  36. Nelson, M.T.; Joksovic, P.M.; Su, P.; Kang, H.W.; Van Deusen, A.; Baumgart, J.P.; David, L.S.; Snutch, T.P.; Barrett, P.Q.; Lee, J.H.; et al. Molecular mechanisms of subtype-specific inhibition of neuronal T-type calcium channels by ascorbate. J. Neurosci. 2007, 27, 12577–12583. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Garcia-Vilas, J.A.; Quesada, A.R.; Medina, M.A. 4-methylumbelliferone inhibits angiogenesis in vitro and in vivo. J. Agric. Food Chem. 2013, 61, 4063–4071. [Google Scholar] [CrossRef]
  38. Shin, H.J.; Kim, H.L.; Kim, S.J.; Chung, W.S.; Kim, S.S.; Um, J.Y. Inhibitory effects of chelidonic acid on IL-6 production by blocking NF-kappaB and caspase-1 in HMC-1 cells. Immunopharmacol. Immunotoxicol. 2011, 33, 614–619. [Google Scholar] [CrossRef]
  39. Amaravani, M.; Prasad, N.K.; Ramakrishna, V. COX-2 structural analysis and docking studies with gallic acid structural analogues. Springerplus 2012, 1, 58. [Google Scholar] [CrossRef] [Green Version]
  40. Kang, M.S.; Oh, J.S.; Kang, I.C.; Hong, S.J.; Choi, C.H. Inhibitory effect of methyl gallate and gallic acid on oral bacteria. J. Microbiol. 2008, 46, 744–750. [Google Scholar] [CrossRef]
  41. Liao, W.C.; Huang, Y.T.; Lu, L.P.; Huang, W.Y. Antioxidant Ability and Stability Studies of 3-O-Ethyl Ascorbic Acid, a Cosmetic Tyrosinase Inhibitor. J. Cosmet. Sci. 2018, 69, 233–243. [Google Scholar]
  42. Ohtoyo, M.; Tamura, M.; Machinaga, N.; Muro, F.; Hashimoto, R. Scintillation Proximity Assay to Detect the Changes in Cellular Dihydrosphingosine 1-Phosphate Levels. Lipids 2016, 51, 1207–1216. [Google Scholar] [CrossRef] [PubMed]
  43. Yang, E.B.; Zhao, Y.N.; Zhang, K.; Mack, P. Daphnetin, One of Coumarin Derivatives, is a Protein Kinase Inhibitor. Biochem. Biophys. Res. Commun. 1999, 260, 682–685. [Google Scholar] [CrossRef] [PubMed]
  44. Han, S.; Li, L.Z.; Song, S.J. Daphne giraldii Nitsche (Thymelaeaceae): Phytochemistry, pharmacology and medicinal uses. Phytochemistry 2020, 171, 112231. [Google Scholar] [CrossRef] [PubMed]
  45. Yang, F.; Jiang, X.; Cao, H.; Shuai, W.; Zhang, L.; Wang, G.; Quan, D.; Jiang, X. Daphnetin Preconditioning Decreases Cardiac Injury and Susceptibility to Ventricular Arrhythmia following Ischaemia-Reperfusion through the TLR4/MyD88/NF-Kappab Signalling Pathway. Pharmacology 2021, 106, 369–383. [Google Scholar] [CrossRef] [PubMed]
  46. Gao, J.; Chen, F.; Fang, H.; Mi, J.; Qi, Q.; Yang, M. Daphnetin inhibits proliferation and inflammatory response in human HaCaT keratinocytes and ameliorates imiquimod-induced psoriasis-like skin lesion in mice. Biol. Res. 2020, 53, 48. [Google Scholar] [CrossRef] [PubMed]
  47. Liu, C.; Pan, J.; Liu, H.; Lin, R.; Chen, Y.; Zhang, C. Daphnetin inhibits the survival of hepatocellular carcinoma cells through regulating Wnt/beta-catenin signaling pathway. Drug Dev. Res. 2022, 1–9. [Google Scholar] [CrossRef]
  48. Wang, Z.Q.; Su, R.J.; Xu, G.L.; Liang, S.L.; Gao, C.X. Clinical observation of 111 cases of angina pectoris with coronary heart disease treated by daphnetin. Chin. J. Gerontol. 1988, 8, 53. [Google Scholar]
  49. Li, X.M.; Guo, S.F.; Liu, F.T. Clinical observation of 112 cases of thromboangiitis obliterans treated by daphnetin. Jilin Med. J. 1986, 7, 28–29. [Google Scholar]
  50. Chiang, C.C.; Cheng, M.J.; Peng, C.F.; Huang, H.Y.; Chen, I.S. A novel dimeric coumarin analog and antimycobacterial constituents from Fatoua pilosa. Chem. Biodivers. 2010, 7, 1728–1736. [Google Scholar] [CrossRef]
  51. Miri, R.; Nejati, M.; Saso, L.; Khakdan, F.; Parshad, B.; Mathur, D.; Parmar, V.S.; Bracke, M.E.; Prasad, A.K.; Sharma, S.K.; et al. Structure-activity relationship studies of 4-methylcoumarin derivatives as anticancer agents. Pharm. Biol. 2016, 54, 105–110. [Google Scholar] [CrossRef] [Green Version]
  52. Nagy, N.; Kuipers, H.F.; Frymoyer, A.R.; Ishak, H.D.; Bollyky, J.B.; Wight, T.N.; Bollyky, P.L. 4-methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer. Front. Immunol. 2015, 6, 123. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Venugopala, K.N.; Rashmi, V.; Odhav, B. Review on natural coumarin lead compounds for their pharmacological activity. Biomed. Res. Int. 2013, 2013, 963248. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Zhang, S.; Ren, Q.C.; Xu, L.; Feng, L.S. Coumarin derivatives and their antituberculous activity. World Notes Antibiot. 2017, 38, S4–S10. [Google Scholar] [CrossRef]
  55. Mangasuli, S.N.; Hosamani, K.M.; Devarajegowda, H.C.; Kurjogi, M.M.; Joshi, S.D. Synthesis of coumarin-theophylline hybrids as a new class of anti-tubercular and anti-microbial agents. Eur. J. Med. Chem. 2018, 146, 747–756. [Google Scholar] [CrossRef] [PubMed]
  56. Duan, C.Y.; Jiang, X.; Zeng, H.W.; Yang, X.L. Immobilization of Isocitrate lyase on Amphoteric Ion-rich Hydrophilic Magnetic Beads. J. Food Sci. Biotechnol. 2021; accepted. [Google Scholar]
  57. Giachetti, E.; Pinzauti, G.; Vanni, P. A new continuous optical assay for isocitrate lyase. Experientia 1984, 40, 227–228. [Google Scholar] [CrossRef]
Molecules 27 02447 g001 550
Figure 1. Active site of MtICL binding with isocitrate.
Figure 1. Active site of MtICL binding with isocitrate.
Molecules 27 02447 g001
Molecules 27 02447 g002 550
Figure 2. Diagram of interactions between MtICL and reference ligands. (A): 3-BP; (B): IA.
Figure 2. Diagram of interactions between MtICL and reference ligands. (A): 3-BP; (B): IA.
Molecules 27 02447 g002
Molecules 27 02447 g003 550
Figure 3. Interaction between daphnetin and MtICL. (A): Docking result of daphnetin with MtICL. Compounds: orange = daphnetin and blue = the amino acids interacting with daphnetin. Interacting bonds: yellow = hydrogen bond; green = electrostatic interaction; orange = π-anion; and pink = π-alkyl. (B): IC50 of daphnetin against MtICL.
Figure 3. Interaction between daphnetin and MtICL. (A): Docking result of daphnetin with MtICL. Compounds: orange = daphnetin and blue = the amino acids interacting with daphnetin. Interacting bonds: yellow = hydrogen bond; green = electrostatic interaction; orange = π-anion; and pink = π-alkyl. (B): IC50 of daphnetin against MtICL.
Molecules 27 02447 g003
Molecules 27 02447 g004 550
Figure 4. Overlapping diagram of four compounds within MtICL active sites. Red = IA; green = isocitric acid; yellow = daphnetin; and blue = 3-BP.
Figure 4. Overlapping diagram of four compounds within MtICL active sites. Red = IA; green = isocitric acid; yellow = daphnetin; and blue = 3-BP.
Molecules 27 02447 g004
Molecules 27 02447 g005 550
Figure 5. Results of MD simulations. (A): RMSF; (B): RMSD.
Figure 5. Results of MD simulations. (A): RMSF; (B): RMSD.
Molecules 27 02447 g005
Table
Table 1. Characterization of the selected compounds.
Table 1. Characterization of the selected compounds.
CompoundStructureInhibition Rate %LibDock Score-Interaction Energy (kcal/mol)Natural ResourceReported Target Name
L-Ascorbic acid Molecules 27 02447 i00120.2 a97.160.0Ginkgo Semen, Herba Patriniae, Corayceps, etc.Cav3.2 channels [36]
4-Methylumbelliferone Molecules 27 02447 i00225.6 a84.555.4OlibanunHyaluronic acid [37]
Quinic acid Molecules 27 02447 i00346.0 a99.852.7Boehmeriae Rhizoma Et Radix-
L-Shikimic acid Molecules 27 02447 i00417.4 a94.452.3Anisi Stellati Fructus-
Chelidonic acid Molecules 27 02447 i00518.5 a95.352.2Chelidonium majus L.NF-κB [38]
Gallic acid Molecules 27 02447 i00628.8 a98.651.6Palm leaf rhubarb, eucalyptus urophylla, dogwood, etc.COX-2 [39]
Phosphatidic acid Molecules 27 02447 i00734.1 b99.857Angelicae Sinensis Radix and Panacis Quinquefolii Radix-
Methyl gallate Molecules 27 02447 i00827.4 b95.754.1Paeoniae Radix Alba, Radix Paeoniae Rubra, Canavaliae Semen, etc.Bacterial [40]
3-O-Ethy-L-ascorbic acid Molecules 27 02447 i00921.9 b93.952.9Hippophae Fructus and Sapindi Mukorossiperic ArpiumTyrosinase [41]
4-Deoxypyridoxine 5′-phosphate Molecules 27 02447 i0103.3 b93.255.6Hippophae FructusSphingosine 1-phosphate [42]
Daphnetin Molecules 27 02447 i011100 b94.856Daphne Korean NakaiEGFR, PKA, and PKC [43]
3-BP Molecules 27 02447 i01263.6 ± 2.8 (μM) c55.741-MtICL [20]
IA Molecules 27 02447 i01338.6 ± 0.8 (μM) c72.954-MtICL [21]
a The final concentration of compounds was 333 μM. b The final concentration of compounds was 500 μg/mL. c IC50.
Table
Table 2. Antibacterial activity of three compounds and control drugs.
Table 2. Antibacterial activity of three compounds and control drugs.
CompoundMIC (μg/mL)
Daphnetin128
3-BP256
IA>256
Streptomycin0.5
Levofloxacin<0.125
Table
Table 3. The results of ADMET calculations.
Table 3. The results of ADMET calculations.
CompoundAbsorption LevelSolubility LevelBBB LevelCYP2D6HepatotoxicPPB
Daphnetin 043FALSETRUEFALSE
3-BP154FALSETRUEFALSE
IA354FALSEFALSEFALSE
Table
Table 4. The results of toxicity prediction.
Table 4. The results of toxicity prediction.
CompoundAmesRat Oral LD50 (mg/kg_Body_Weight)Rat Inhalational LC50 (mg/m3/h) DTP Probability
DaphnetinNon-mutagen474.362305.350.61
3-BPNon-mutagen219.282599.560.53
IANon-mutagen1209.332050.050.55
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Duan, C.; Jiang, Q.; Jiang, X.; Zeng, H.; Wu, Q.; Yu, Y.; Yang, X. Discovery of a Novel Inhibitor Structure of Mycobacterium tuberculosis Isocitrate Lyase. Molecules 2022, 27, 2447. https://doi.org/10.3390/molecules27082447

AMA Style

Duan C, Jiang Q, Jiang X, Zeng H, Wu Q, Yu Y, Yang X. Discovery of a Novel Inhibitor Structure of Mycobacterium tuberculosis Isocitrate Lyase. Molecules. 2022; 27(8):2447. https://doi.org/10.3390/molecules27082447

Chicago/Turabian Style

Duan, Changyuan, Qihua Jiang, Xue Jiang, Hongwei Zeng, Qiaomin Wu, Yang Yu, and Xiaolan Yang. 2022. "Discovery of a Novel Inhibitor Structure of Mycobacterium tuberculosis Isocitrate Lyase" Molecules 27, no. 8: 2447. https://doi.org/10.3390/molecules27082447

APA Style

Duan, C., Jiang, Q., Jiang, X., Zeng, H., Wu, Q., Yu, Y., & Yang, X. (2022). Discovery of a Novel Inhibitor Structure of Mycobacterium tuberculosis Isocitrate Lyase. Molecules, 27(8), 2447. https://doi.org/10.3390/molecules27082447

Article Metrics

Back to TopTop